Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Isolation of Tiliroside from Spiranthera odoratissima as Inhibitor of Trypanosoma cruzi Glyceraldehyde-3-phosphate Dehydrogenase by Using Bioactivity-Guided Fractionation

Texto completo
Autor(es):
Cornelio, Vivian E. ; Maluf, Fernando V. ; Fernandes, Joao B. ; da Silva, Maria Fatima G. F. ; Oliva, Glaucius ; Guido, Rafael V. C. ; Vieira, Paulo C.
Número total de Autores: 7
Tipo de documento: Artigo Científico
Fonte: Journal of the Brazilian Chemical Society; v. 28, n. 3, SI, p. 512-519, MAR 2017.
Citações Web of Science: 7
Resumo

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a key enzyme involved in the Trypanosoma cruzi glycolytic pathway, parasite that causes Chagas' disease. There are only few drugs available to treat this disease, most of which present strong side effects. Natural products constitute a prime source for the discovery of new scaffolds potentially useful for the treatment of several diseases, including Chagas' disease. Bioactivity-guided fractionation of Spiranthera odoratissima extract using T. cruzi GAPDH (TcGAPDH) as a target led to the isolation of the flavonoid tiliroside (kaempferol-3-O-beta-D-(6''-trans-p-coumaroyl)-glucopyranoside), identified as an excelent inhibitor of this enzyme and for the first time reported for this plant species. Mechanistic studies of tiliroside showed that it is a reversible non-competitive inhibitor of TcGAPDH. In additon, molecular modeling analysis indicated the binding mode of tiliroside to TcGAPDH. Therefore, the identification of tiliroside as TcGPADH inhibitor in a complex matrix such as the plant crude extract and the discovery of a new binding site may contribute to the opening of new paths in the search for natural product inhibitors of this enzyme. (AU)

Processo FAPESP: 09/17538-8 - Estudo de novas metodologias para realização de ensaios com a catepsina D na busca de inibidores
Beneficiário:Vivian Estevam Cornélio
Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
Processo FAPESP: 13/07600-3 - CIBFar - Centro de Inovação em Biodiversidade e Fármacos
Beneficiário:Glaucius Oliva
Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs